Avidity Biosciences Ownership
| RNA Stock | USD 32.63 0.71 2.22% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 106.9 M | Current Value 123.4 M | Avarage Shares Outstanding 50.4 M | Quarterly Volatility 28.8 M |
Avidity |
Avidity Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The book value of Avidity Biosciences was at this time reported as 12.64. The company recorded a loss per share of 2.88. Avidity Biosciences had not issued any dividends in recent years. Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Avidity Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 125 people. To find out more about Avidity Biosciences contact Sarah Boyce at 858 401 7900 or learn more at https://www.aviditybiosciences.com.Besides selling stocks to institutional investors, Avidity Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Avidity Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Avidity Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Avidity Biosciences Quarterly Liabilities And Stockholders Equity |
|
Avidity Biosciences Insider Trades History
About 5.0% of Avidity Biosciences are currently held by insiders. Unlike Avidity Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Avidity Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Avidity Biosciences' insider trades
Avidity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avidity Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avidity Biosciences backward and forwards among themselves. Avidity Biosciences' institutional investor refers to the entity that pools money to purchase Avidity Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.6 M | Casdin Capital, Llc | 2024-09-30 | 2.1 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Polar Capital Holdings Plc | 2024-09-30 | 1.5 M | Siren, L.l.c. | 2024-09-30 | 1.4 M | Bank Of America Corp | 2024-09-30 | 1.3 M | Artisan Partners Limited Partnership | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.1 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 16.8 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 10.6 M |
Avidity Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avidity Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avidity Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avidity Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avidity Biosciences Outstanding Bonds
Avidity Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avidity Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avidity bonds can be classified according to their maturity, which is the date when Avidity Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AVA 4 01 APR 52 Corp BondUS05379BAR87 | View | |
| AVISTA P 435 Corp BondUS05379BAQ05 | View | |
| Avis Budget Car Corp BondUS053773BC09 | View | |
| AVIS BUDGET CAR Corp BondUS053773BE64 | View | |
| US053773BF30 Corp BondUS053773BF30 | View | |
| US053773BG13 Corp BondUS053773BG13 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Avidity Biosciences Corporate Filings
F4 | 23rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth (0.17) | Return On Assets | Return On Equity |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.